Alkahest, Inc. is a biotech company, focus on development of therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline.
Alkahest was established by Drs. Tony Wyss-Coray and Karoly Nikolich to further develop and commercialize the pioneering work of Dr. Wyss-Coray, and other leading scientists at Stanford University who demonstrated that factors in the blood of young animals were able to restore mental capabilities in old animals.
Alkahest, Inc. is a biotech company, focus on development of therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline.
Alkahest was established by Drs. Tony Wyss-Coray and Karoly Nikolich to further develop and commercialize the pioneering work of Dr. Wyss-Coray, and other leading scientists at Stanford University who demonstrated that factors in the blood of young animals were able to restore mental capabilities in old animals.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/alkahest-inc-” connections=”true” suffix=””]
In Mar 2015, Grifols acquires 45% of the equity of Alkahest for $37.5 Mn. Also, in addition Grifols to further provide a payment of $12.5 Mn and fund the development of plasma-based products, which may be commercialized by Grifols throughout the world.
Alkahest acquired ALK4290 from Boehringer-Ingelheim and has exclusive rights for development, commercialization worldwide.
May 2018, Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support Preclinical Evaluation of ALK4290 and GRF6019 for Parkinsons Disease.
In Jul 2014, Alkahest, raised $3.50 Mn in series A financing round. In addition to Grifols, Alkahests investors include Bioville Investment Limited, Full House Investment Limited and Stanford University.
Recover your password.
A password will be e-mailed to you.